Skip to main content
  • KABUKI Trial: Edoxaban Noninferior to Warfarin to Prevent Pulmonary Vascular Resistance in CTEPH

    A 48-week course of edoxaban was non-inferior to warfarin in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as treatment to prevent pulmonary vascular resistance, new trial results show.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details